Comparative Pharmacology
Head-to-head clinical analysis: EFAVIRENZ EMTRICITABINE TENOFOVIR DISOPROXIL FUMARATE versus EFAVIRENZ LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EFAVIRENZ EMTRICITABINE TENOFOVIR DISOPROXIL FUMARATE versus EFAVIRENZ LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE.
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE vs EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds reversibly to HIV-1 reverse transcriptase, causing a conformational change and inhibiting RNA-dependent and DNA-dependent DNA polymerase activity. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) that, after intracellular phosphorylation, competes with deoxycytidine 5'-triphosphate and incorporates into viral DNA, causing chain termination. Tenofovir disoproxil fumarate is an acyclic nucleoside phosphonate diester analog of adenosine monophosphate that, after hydrolysis and phosphorylation, inhibits HIV-1 reverse transcriptase and hepatitis B virus DNA polymerase by competing with deoxyadenosine 5'-triphosphate and causing DNA chain termination.
EFAVIRENZ: Non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds to HIV-1 reverse transcriptase, causing allosteric inhibition and blocking RNA-dependent DNA polymerase activity. LAMIVUDINE: Nucleoside reverse transcriptase inhibitor (NRTI) that is phosphorylated to its active triphosphate metabolite, which competes with endogenous deoxycytidine triphosphate for incorporation into viral DNA, causing chain termination. TENOFOVIR DISOPROXIL FUMARATE: Prodrug of tenofovir, an NRTI that, after hydrolysis and phosphorylation, inhibits HIV-1 reverse transcriptase by competing with deoxyadenosine triphosphate and causing DNA chain termination.
One tablet (efavirenz 600 mg / emtricitabine 200 mg / tenofovir disoproxil fumarate 300 mg) orally once daily on an empty stomach, preferably at bedtime.
One tablet (efavirenz 600 mg, lamivudine 300 mg, tenofovir disoproxil fumarate 300 mg) orally once daily on an empty stomach, preferably at bedtime.
None Documented
None Documented
Efavirenz: 40-55 hours (single dose), 52-76 hours (steady state). Emtricitabine: 10 hours (healthy), extended to >20 hours in renal impairment. Tenofovir: 17 hours (healthy), prolonged in renal impairment (up to 7 days with CrCl <30 mL/min).
Efavirenz: 40-55 h (single dose), 50-76 h (multiple doses). Lamivudine: 5-7 h (adults). Tenofovir: 17 h (single dose), 12-17 h (multiple doses) in cells up to 48-60 h. Clinical context: Efavirenz's long half-life allows once-daily dosing; tenofovir's long intracellular half-life supports once-daily dosing.
Efavirenz: ~14-34% excreted in urine (primarily as metabolites) and ~16-61% in feces. Emtricitabine: ~86% excreted unchanged in urine and ~14% as metabolites. Tenofovir disoproxil fumarate: ~70-80% excreted unchanged in urine via glomerular filtration and active tubular secretion.
Efavirenz: 14-34% renal (mostly metabolites), 16-61% fecal (parent drug and metabolites). Lamivudine: ~70% renal (unchanged via active tubular secretion). Tenofovir disoproxil fumarate: 70-80% renal (unchanged as tenofovir via glomerular filtration and active secretion).
Category A/B
Category A/B
NRTI
NRTI